Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,360 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HER2- Breast Cancer Clear all
Completed Phase 1 Interventional

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

NCT03219268
View directory record Official record
Conditions
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer

NCT00148668
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, Navelbine, Taxotere, Carboplatin
Drug
Lead sponsor
Eric Winer, MD
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 28, 2026, 4:03 PM EDT
Completed No phase listed Observational

Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2

NCT00071383
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

NCT00526045
View directory record Official record
Conditions
Breast Cancer, Hematologic Neoplasms
Interventions
AUY922 2 mg/m2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
7
States / cities
Los Angeles, California • Augusta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 28, 2026, 4:03 PM EDT
Withdrawn Phase 1 Interventional

Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer

NCT05634954
View directory record Official record
Conditions
Breast Cancer
Interventions
GEH121224 (18F) Injection, Dynamic and Static - PET/CT Scan, Static - PET/CT Scan
Drug · Diagnostic Test
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

NCT00490139
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
260
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 221 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

NCT02273973
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo, Taselisib
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 28, 2026, 4:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

NCT02615054
View directory record Official record
Conditions
Trastuzumab Cardiotoxicity, HER2-Positive Breast Cancer Survivors
Interventions
2D Echocardiogram, Cardiopulmonary exercise testing and post-CPET cardiac function
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 28, 2026, 4:03 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

NCT07540572
View directory record Official record
Conditions
ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
Interventions
IDE574, Fulvestrant injection
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years to 99 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Plantation, Florida • East Brunswick, New Jersey • Lake Success, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

NCT04319757
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
Interventions
ACE1702, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Acepodia Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

NCT00513292
View directory record Official record
Conditions
HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
Cyclophosphamide, Epirubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Therapeutic Conventional Surgery, Trastuzumab
Drug · Other · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
114
States / cities
Mobile, Alabama • Castro Valley, California • Greenbrae, California + 83 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT03778931
View directory record Official record
Conditions
Breast Cancer
Interventions
Elacestrant, Standard of Care
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
104
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Fullerton, California + 84 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Results available

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

NCT01209195
View directory record Official record
Conditions
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Interventions
MM-121, Paclitaxel
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Oct 28, 2026, 4:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Asciminib in HER2+ Breast Cancer Brain Metastases

NCT07136428
View directory record Official record
Conditions
HER2+ Metastatic Breast Cancer
Interventions
Asciminib and Trastuzumab
Combination Product
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

NCT00667251
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, docetaxel, lapatinib ditosylate, paclitaxel
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
53
States / cities
Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 28, 2026, 4:03 PM EDT
Terminated Not applicable Interventional

PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

NCT01712815
View directory record Official record
Conditions
HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
laboratory biomarker analysis, pharmacological study, questionnaire administration, fluorine F 18-clevudine, positron emission tomography/computed tomography
Other · Radiation · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

NCT01226316
View directory record Official record
Conditions
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive
Interventions
AZD5363
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

NCT00127933
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine [Xeloda], Taxotere, Herceptin (HER2-neu positive patients only)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
38
States / cities
Los Angeles, California • Montebello, California • Palm Springs, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2011 · Synced Oct 28, 2026, 4:03 PM EDT
Completed No phase listed Observational

HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program

NCT02616133
View directory record Official record
Conditions
Breast Cancer
Interventions
chart abstraction
Other
Lead sponsor
Duke University
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Marquette, Michigan • Henderson, North Carolina • West Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 4:03 PM EDT
Terminated Phase 1 Interventional

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

NCT06714617
View directory record Official record
Conditions
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer
Interventions
BL-M17D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

NCT03112590
View directory record Official record
Conditions
Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
Interventions
Interferon-gamma (IFN-γ), Paclitaxel, Trastuzumab, Pertuzumab, Post Therapy Surgery
Biological · Drug · Other + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 28, 2026, 4:03 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823
View directory record Official record
Conditions
Breast Cancer
Interventions
Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
368
States / cities
Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 28, 2026, 4:03 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

NCT02957968
View directory record Official record
Conditions
Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive Tumor, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-negative Breast Carcinoma
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Edgewood, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 28, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

NCT03544125
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Durvalumab, Olaparib
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 28, 2026, 4:03 PM EDT